In conclusion, the addition of mAbs such as anti-programmed cell death protein 1/programmed death-ligand 1 or epidermal growth factor receptor inhibitors or vascular endothelial growth factor inhibitors to platinum-doublet chemotherapy markedly improved the overall survival and survival rates of NSCLC patients. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.